Breath of fresh air for inhaled insulins?
This article was originally published in Scrip
Executive Summary
MannKind Pharmaceuticals has presented new clinical trial data on its inhaled insulin Afresa, suggesting that the medicine is comparable to the standard of care. While this news spurred confidence in the market, causing a 14% rise in the company's share price on June 8th, some analysts remained unimpressed with the data.